Ontology highlight
ABSTRACT:
SUBMITTER: Choueiri TK
PROVIDER: S-EPMC5024539 | biostudies-literature | 2015 Nov
REPOSITORIES: biostudies-literature
Choueiri Toni K TK Escudier Bernard B Powles Thomas T Mainwaring Paul N PN Rini Brian I BI Donskov Frede F Hammers Hans H Hutson Thomas E TE Lee Jae-Lyun JL Peltola Katriina K Roth Bruce J BJ Bjarnason Georg A GA Géczi Lajos L Keam Bhumsuk B Maroto Pablo P Heng Daniel Y C DY Schmidinger Manuela M Kantoff Philip W PW Borgman-Hagey Anne A Hessel Colin C Scheffold Christian C Schwab Gisela M GM Tannir Nizar M NM Motzer Robert J RJ
The New England journal of medicine 20150925 19
<h4>Background</h4>Cabozantinib is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiology of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs. This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after ...[more]